Kornimate/medical-research-clean huggingface dataset:
pancreas borderline and locally advanced snapshot study

Conditions: Pancreatic Cancer

Summary: the project's objective is to carry out prospectively, in france, for one year, a descriptive registry study in the management of patients with borderline or locally advanced pancreatic adenocarcinoma, and to collect both the patient's demographic characteristics, but also the therapeutic regimens applied, the types of surgeries performed and the outcome of the patients after surgery, and at three months of follow up (preoperative data, complications's post surgery, quality of the resection, etc.)

* multicenter, observational prospective study over one year in france in patients with borderline or locally advanced pancreatic adenocarcinoma operated between september 2022 and august 2023. * patients will be screened by the pancreatic's surgeons practicing in a reference centers during preoperative surgical consultations (v1), * the patient's non-objection will be sollected, * the end of follow-up's patient will take place during the post-operative consultation approximately 3 months after surgery (v3) * between v1 and v3, preoperative data (demography, history, tumor characteristics, neoadjuvant treatments performed, tumor response), operative, intraoperative, pathological and postoperative data will be collected via a e-crf " the redcap software".

Eligibility criteria:
inclusion criteria: * any patient over the age of 18, operated on for pancreatic adenocarcinoma, borderline or locally advanced, between september 2022 and august 2023, in france * diagnosis of pancreatic adenocarcinoma: * either after cytopuncture with anatomopathological result confirming the diagnosis, * or with strong suspicion on the combined criterias : clinical, biological and morphological criterion (according to inca 2019 and nccn recommendations ) in the event of absence of anatomopathological documentation (failure of several fine needle punctures (maximum 3)/or non-contributory anatomopathological examinations), * borderline or locally advanced character depending on the presence of a contact of the tumor with nearby vessels and defined by morphological examination (scanner +/- mri). these criteria are defined by the nccn guidelines for pancreatic adenocarcinoma v.1.2021, international reference exclusion criteria: * patient under juridic protected or subject to any measure of legal protection, * patients not operated on for their pancreatic adenocarcinoma, * adenocarcinoma of the pancreas operable immediately on diagnosis, * metastatic pancreatic adenocarcinoma from the outset on diagnosis, * patient without pancreatic adenocarcinoma after histological examination (in the case where the pancreatic lesion was operated on for strong suspicion of pancreatic adenocarcinoma on the combined clinical, biological and morphological criterion (according to inca 2019 and nccn recommendations, but that the lesion on definitive pathological examination is not a pancreatic adenocarcinoma)

Keywords: pancreatic cancer adenocarcinoma locally advanced cancer
web-based cbt for children with chronic pain

Conditions: Chronic Pain; Headache; Abdominal Pain

Summary: the purpose of this study is to develop and evaluate the feasibility and effectiveness of a web-based (i.e., internet) treatment approach for providing psychological treatment to reduce pain and improve functioning in children and adolescents with chronic pain.

chronic pain is an important problem for children and adolescents owing to its high prevalence rate and significant impact on children's mood, daily functioning, and overall quality of life. effective psychological treatments have been developed to change behaviors and thoughts important in the child's ability to cope with chronic pain. however, the majority of children do not have access to these treatments due to a variety of barriers such as geographical distance from pediatric pain treatment centers. the purpose of this study is to develop a more accessible method of delivering effective psychological treatment to reduce pain and increase function in children. children with chronic headache, abdominal, or musculoskeletal pain will be randomized to either receive the web-based treatment right away or to be in a wait-list control condition and receive the treatment 8 weeks later. both groups of children will continue to receive clinical care through specialty medical clinics. children's level of pain, their ability to perform, daily functional activities, and overall quality of life will be evaluated before treatment begins, immediately after treatment, and at a 3 month follow up.

Eligibility criteria:
inclusion criteria: * chronic headache, abdominal, and/or musculoskeletal pain present over the previous 3 months * interference from pain in at least one area of daily functioning. exclusion criteria: * serious comorbid chronic condition in the patient (e.g., diabetes, cancer) * non-english speaking * previous participation in cognitive-behavioral therapy.

Keywords: cognitive-behavioral therapy chronic pain randomized controlled trial pediatrics
diagnostic and prognostic model of pulmonary fibrosis after covid-19 pneumonia and mechanism study

Conditions: Pulmonary Fibrosis; COVID-19

Summary: the infection of covid-19 has caused serious threat to the life and health of all mankind and increased huge economic burden. according to the current statistics, the incidence of pulmonary fibrosis after covid-19 infection is about 27.7% -87%, 81% of severe patients and 37% of moderate patients have residual lung lesions, and 53% of patients still have residual lung abnormalities one year after infection, resulting in restrictive pulmonary dysfunction and affecting the health and life of patients. therefore, it is very important to study the diagnostic and prognostic markers of pulmonary fibrosis after infection of covid-19. at present, relevant studies have been carried out on imagomics and serum proteomics of pulmonary fibrosis after covid-19 infection, and serum biomarkers and imagomics marker models for diagnosing pulmonary fibrosis after covid-19 pneumonia have been developed. however, there are few studies combining imageomics and serum proteomics, and the mechanism of pulmonary fibrosis after covid-19 has not been fully clarified. in this study, it is planned to recruit patients with moderate, severe and critical covid-19 pneumonia infection, collect venous blood from subjects, and perform chest hrct follow-up. blood samples were screened by proteomics and verified by expanded samples to screen diagnostic and prognostic markers of pulmonary fibrosis after covid-19 infection. at the same time, based on deep learning technology, a model was developed to predict the occurrence and prognosis of pulmonary fibrosis after infection of covid-19 combined with clinical characteristics, serum markers and ai imagomics, so as to provide ideas for further elucidating the mechanism of occurrence and development of pulmonary fibrosis after infection of covid-19.


Eligibility criteria:
inclusion criteria: 1. age 18-90 years 2. novel coronavirus nucleic acid or antigen confirmed novel coronavirus infection 3. meet the diagnostic criteria for moderate/severe/severe coronavirus infection in china (trial tenth edition) 4. chest ct showed that the extent of lung lesions was greater than 50% exclusion criteria: 1. pregnant and lactating women 2. previous severe lung disease, such as known chronic lung disease: chronic obstructive pulmonary disease, asthma, interstitial lung disease, etc. 3. severe organ dysfunction: severe liver, kidney and heart dysfunction 4. severe epidemic defects (including tumors/severe rheumatism/organs, bone marrow transplantation/hiv, etc.) 5. inappropriate enrollment judged by the investigator
the posturing after retinal detachment (post rd) trial

Conditions: Retinal Detachment

Summary: a randomised controlled trial to evaluate the effect of face-down posturing on retinal displacement and distortion following retinal detachment repair.

during the surgical repair of a retina detachment, a gas bubble is inserted into the eye to keep the retina flat. following this, it is common to ask patients to adopt a certain head position for a set period of time after their operation. this is known as posturing. it is thought that by adopting a certain head position/posturing, the bubble aids re-attachment of the retina. however, when the retinal detachment involves the macula (central portion of the retina) it has been shown that the retina can shift (or displace) post-operatively, leading to distortion in the patient's vision. the purpose of this study is to investigate whether adopting different head positions following surgery for macula involving retinal detachments, can reduce retinal displacement and visual distortion. the investigators plan to recruit 368 patients. patients will be in follow up for a period of six months. the study will be operational at two different hospitals in the united kingdom.

Eligibility criteria:
inclusion criteria: * fovea-involving rhegmatogenous retinal detachment * history of central visual loss within the past 14 days * patients undergoing vitrectomy and gas surgery, under local anaesthetic * able to give informed consent * 18 years old and over exclusion criteria: * previous vitrectomy or cryo-buckle surgery * retinal detachment surgery requiring silicone oil tamponade * existing ophthalmic condition which limits the patient's visual acuity (bcva 6/36 or worse) * inability to posture post-operatively or commit to follow-up visits
integrated cognitive, sensory, and motor rehabilitation of hand functions

Conditions: Stroke

Summary: this study evaulates the addition to the standard theraphy of enriched sensorimotor training by means of robotic glove therapy, or functional electrical stimulation in the treatment of chronic stroke patients with upper limb motor impairments. all the patients receive the conventional physiotherapic treatment. supplemental to the conventional treatment, patients are evenly split in four groups to provide different treatments for an equivalent amount of time. patient in the first group receive supplemental conventional therapy; patients in the second group receive robotic glove therapy; patients in the third group receive functional electrical stimulation; patients in the fourth group receive robotic glove treatment and functional electrical stimulation in different sessions.

stroke very frequently impacts on patients' motor function, and particularly on upper limb movements. limited hand functionality is a major negative outcome after stroke, negatively affecting patients' recovery and independence, with major impact on rehabilitation.however, standard motor rehabilitation outcome is often suboptimal, because insufficient or non-specific treatment is provided. robotic hand mobilization and functiona electrical stimulation grasp rehabilitation each improve motor capabilities in grasp impaired patients, but they do so by different mechanisms. robotic hand mobilization achieves grasp rehabilitation by providing passive mobilization of the affected limb if the subject does not react to the designed task. functional electrical stimulation achieves grasp rehabilitation by inducing localized muscle contraction, that is by providing an electrical field able to stimulate both sensory afferent pathways and lower motor neurons in the targeted volume.

Eligibility criteria:
inclusion criteria: * adults male and/or female, older than 18 years * patients who have suffered one or more strokes with major unilateral functional impairment * hemiplegic, left and right unilateral lesion * chronic phase of stroke at least six months before study enrollment * level of impairment: hand and/or arm * no left handed * mini-mental state examination \> 20 exclusion criteria: * limitation for using the device due to impairment of passive range of motion and/or * pain due to spasticity evaluated using modified ashworth scale (\>=3) * previous history of major neurological or psychiatric disorders * allergy to electrodes

Keywords: rehabilitation functional electrical stimulation electrode array upper limb chronic motor relearning
comparison of indacaterol 150 mcg once daily (o.d.) with salmeterol/fluticasone propionate 50 mcg/500 mcg twice daily (b.i.d.)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to compare the effectiveness and safety of indacaterol with salmeterol /fluticasone propionate treatment in patients with moderate chronic obstructive pulmonary disease who, on entry to the study are being treated with salmeterol /fluticasone propionate.


Eligibility criteria:
inclusion criteria: * patients with moderate copd (stage ii) * able to perform spirometry assessments * current or ex-smokers * on treatment with the fixed-dose combination of salmeterol 50 µg/fluticasone propionate 500 µg mddpi b.i.d. for the treatment of copd for ≥ 3 months directly preceding visit 1. exclusion criteria: * having had a copd exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization in the past year. * having a history of, or current ecg abnormality * asthma other protocol-defined inclusion/exclusion criteria may apply.

Keywords: chronic obstructive pulmonary disease indacaterol salmeterol/fluticasone propionate
preserving fertility after colorectal cancer study

Conditions: Colorectal Cancer

Summary: the preface study is a prospective, longitudinal cohort study of reproductive health and clinical outcomes among individuals diagnosed with colorectal cancer between age 18 to 49 years.

the preserving fertility after colorectal cancer (preface) study comprehensively investigates fertility, sexual health and clinical outcomes along the cancer care continuum among individuals diagnosed with colorectal cancer between age 18 to 49 years. patients are recruited prior to colorectal cancer therapy \[baseline\] and followed for up to 36 months after completion of first-course therapy (or 45 months after diagnosis for patients on maintenance therapy). study timepoints are defined at: (i) completion of first-course treatment (or 9 months after diagnosis for patients on maintenance therapy \[treatment\]); (ii) and at 9, 18 and 36 month intervals thereafter \[surveillance\]. this cohort is enriched by a robust collection of biospecimens and data.

Eligibility criteria:
inclusion criteria: * known diagnosis of colorectal cancer * age 18 to 49 years at colorectal cancer diagnosis * diagnosed by and/or consulting with a physician participating in the preface study * no prior history of colorectal cancer and/or colorectal cancer treatment * mentally and physically able to consent and participate in the study exclusion criteria: * women who are pregnant at the time of colorectal cancer diagnosis * prisoners * unable to provide informed consent * unable to read, write, or complete questionnaires in english
a pilot study of standard-dose rituximab, ifosfamide, carboplatin and etoposide (rice) plus bortezomib (velcade) in a dose-escalating fashion for patients with relapsed or primary refractory aggressive b-cell non-hodgkin's lymphoma who are candidates for autologous stem cell transplant

Conditions: Lymphoma, B-Cell

Summary: this study seeks to determine the maximum tolerated dose of bortezomib in combination with rituximab, ifosfamide, carboplatin, and etoposide for patients with relapsed or primary refractory aggressive b-cell non-hodgkin's lymphoma (diffuse large b-cell, mantle cell, follicular grade iii, transformed lymphoma). subjects will be enrolled in cohorts of 3 at each bortezomib dose level, starting at 1 mg/m(2), and escalating to 1.3, 1.5, and 1.7 mg/m(2). bortezomib will be given on days 1 (prior to rituximab) and 4, rituximab 375 mg/m(2)/day on days 2, 3, and 4 of a 21-day cycle. they will also receive filgrastim on days 6-13 or pegfilgrastim on day 6.


Eligibility criteria:
inclusion criteria: * aggressive b-cell lymphoma, cd-20 positive, in first relapse or refractory to first-line chemotherapy * diffuse large b-cell lymphoma, mantle cell lymphoma, follicular lymphoma (grade iii), transformed follicular lymphoma * rituximab is allowed * prior radiation is allowed * 18-70 years of age * ecog performance status of 0-2 * hiv seronegative * measurable disease on ct scan by international working group response criteria * no cns involvement * subject is considered to be a candidate for autologous stem cell transplant in the opinion of the treating physician * female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control * male subject agrees to use an acceptable method of contraception for the duration of the study exclusion criteria: * platelet count of \<75 x 10(9)/l * absolute neutrophil count of \<1.0 x 10(9)/l * calculated or measured creatinine clearance of \<60 ml/minute within 14 days before enrollment * myocardial infarction within 6 months prior to enrollment or has new york hospital association class iii or iv heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. prior to study entry, any ecg abnormality at screening has to be documented by the investigator as not medically relevant. * subject has hypersensitivity to bortezomib, boron or mannitol. * female subject is pregnant or breast-feeding. * subject has been treated with more than one prior chemotherapy regimen. * subject has received other investigational drugs with 14 days before enrollment. * serious medical or psychiatric illness likely to interfere with participation in this clinical study.

Keywords: b-cell nhl autologous stem cell transplant rice
contact relationship in neonatal intensive care unit

Conditions: Preterm Birth; Postpartum Depression

Summary: the present research project aims to explore the value that contact relationships between caregivers and the preterm infant may have in terms of promoting developmental and maturational processes,by attending to the neurobehavioral states of the infant in response to maternal and paternal voice. the study is aimed at furthering the still underdeveloped knowledge regarding the possible effects of the paternal voice on the neurobehavioral states of the preterm infant in the crib, comparing them with the effects of exposure to the maternal voice and the voice of a familiar but non-parental figure, such as the nicu nurse. these behavioral states will also be observed as a function of the psychological condition of the parents, investigating the presence of a possible postpartum depressive condition and/or anxiety of the mother and symptomatology attributable to perinatal affective disorders in the fathers, which are often overlooked; and again, the neurobehavioral responses of the infants will be correlated with the neurophysiological responses of the parents/nurses who interact with them through voice and touch. the research aims to have a direct impact on both parents and health care personnel: in addition to questionnaires dedicated to screening parents for perinatal psychological disorders, artificial intelligence systems will be used to intercept possible postpartum depression early by recording the maternal voice, enabling the activation of a psychological support intervention and reducing the negative impact that a postpartum depression has on the early mother-child relationship. in addition, information on parent-child interactive modalities will be able to further guide the intake of assignment and particularly the accompaniment of parents during the time of hospitalization.


Eligibility criteria:
inclusion criteria: * for infants: infants with gestational age between 33 and 36 weeks, weighing around 2kg (lbw - low birth weight), in whom life-threatening conditions have been averted and in stable medical condition will be included in the study. * for parents: male and female adults aged between 18 and 50 years. exclusion criteria: * for infants: presence of congenital anomalies, neurological disorders, genetic syndromes, and any other condition of developmental atypicality. * for parents: parents under 18 years of age; parents with diagnosed psychiatric disorders and/or sensory disabilities; single parents.

Keywords: preterm birth contact relationship postpartum depression
development of a new critical pathway for treatment of acute bacterial skin and skin structure infections (absssi)

Conditions: Bacterial Infections; Acute Bacterial Skin and Skin Structure Infection

Summary: the purpose of this study is to assess the effect of a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) compared to usual care for the treatment of abssi (acute bacterial skin and skin structure infections)


Eligibility criteria:
inclusion criteria: * admitted patients who meets the clinical definition for acute bacterial skin and skin structure infections (absssi) * known or suspected gram-positive infection. exclusion criteria: * known or suspected gram-negative infections, anaerobic infections, or fungemia * known or suspected infections that are severe, life threatening or are not included in the absssi food and drug administration (fda) guidance * injection drug users with a fever * severe neurological disorder leading to immobility or confined to a wheelchair * bilateral lower extremity involvement of the suspected infection.

Keywords: critical pathways health facilities clinical protocols patient satisfaction absenteeism anti-bacterial agents quality of life economics, medical health resources health resource utilization acute bacterial skin and skin structure infection (absssi)
adenosine vs diltiazem for treatment of svt in the ed

Conditions: Supraventricular Tachycardia (SVT)

Summary: this is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the emergency department.


Eligibility criteria:
inclusion criteria: 1. adult patients (18 years and older) 2. diagnosis of acute, stable svt in the emergency department exclusion criteria: 1. receipt of iv av-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting). 2. reported or confirmed personal history of wolff-parkinson-white (wpw) syndrome 3. history of heart failure with reduce ejection fraction (hfref) (lvef\</= 40%) 4. severe bronchoconstrictive lung disease 5. prior hypersensitivity to study medication 6. previously enrolled in pilot study 7. pregnant 8. incarcerated

Keywords: diltiazem adenosine emergency medicine